一期与二期置换关节成形术治疗假体周围感染:前瞻性随机试验
这项前瞻性多中心随机试验比较一期与二期置换关节成形术治疗初次全髋或全膝关节置换术后慢性假体周围感染(PJI)的效果,共随机323例(一期166例,二期157例)。2年随访时,一期组成功率为97%(131/135),二期组为91%(112/123)(p=0.04),一期组总体成功优势比为3.22(95%CI 1.0至10.38),校正特定变量后仍为3倍。结论表明在严格遵循所述方案的前提下,一期治疗对慢性PJI的疗效不劣于二期治疗。
要点
- 一期治疗2年成功率为97%,二期为91%,差异有统计学意义(p=0.04)。
- 一期组总体成功优势比为3.22(95%CI 1.0至10.38),校正后仍为3倍。
- 结论仅适用于严格遵循本试验方案的患者,不应外推至其他人群。
核心结论
- 在严格遵循本试验所述方案的前提下,一期置换关节成形术治疗初次全髋或全膝关节置换术后慢性PJI的2年成功率(97%)不劣于二期治疗(91%)。
研究设计与样本
- 前瞻性、多中心、随机对照试验,纳入初次全髋或全膝关节置换术后慢性PJI且已知病原体的患者,感染定义符合MSIS标准。
- 排除既往翻修、培养阴性感染、真菌感染、免疫抑制或软组织受累无法闭合伤口的患者。
- 共随机323例(一期166例,二期157例),2年随访时纳入分析258例(一期135例,二期123例)。
主要发现
- 一期组16例、二期组9例在2年随访前死亡。
- 2年成功率:一期组97%(131/135),二期组91%(112/123)(p=0.04)。
- 回归分析显示一期组总体成功优势比为3.22(95%CI 1.0至10.38);校正McPherson宿主分级、耐药菌和引流窦道后,一期治疗仍有3倍成功优势。
关键数值与推荐
- 临床成功定义为:无临床失败或同一/新病原体再感染;无因PJI再手术;无PJI相关死亡。
- 所有患者均采用双器械设置,并遵循相似的冲洗和抗生素方案。
- 患者按McPherson宿主分期系统分类,两组人口学和宿主分类相似。
临床怎么用
- 对于符合本试验纳入标准的慢性PJI患者,在严格遵循双器械设置、冲洗和抗生素方案的前提下,可考虑一期置换关节成形术。
- 不应将结果外推至其他患者队列和临床情况。
局限性
- 部分患者失访或死亡,2年随访分析仅纳入258/323例。
- 结论仅适用于严格遵循本试验方案的情况, extrapolation to other patient cohorts and clinical situations should be avoided.
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A 2-stage approach is most commonly used to treat periprosthetic joint infection (PJI). Some successful studies of the 1-stage approach were underpowered, lacked a 2-stage comparative group, and excluded patients with draining sinuses, comorbidities, and/or antibiotic-resistant organisms. Given the morbidity and expense associated with 2-stage treatment, we conducted a prospective, multicenter, randomized trial to compare the results of 1- and 2-stage PJI treatment, specifically including patients with draining sinuses, comorbidities, and resistant organisms. METHODS: Patients presenting for surgical treatment of a chronic PJI with a known organism following primary total hip or knee arthroplasty were included (with infection defined by Musculoskeletal Infection Society [MSIS] criteria). Patients with prior revision, culture-negative infection, or fungal infection, or who were immunosuppressed or had soft-tissue involvement precluding wound closure, were excluded. Patients were classified according to the McPherson host staging system. Clinical success was defined as (1) no clinical failure or reinfection with the same or new organism; (2) no reoperation for PJI; and (3) no PJI-related death. A double-instrument setup was used for all patients, as were similar irrigation and antibiotic protocols. A total of 323 patients (166 one-stage; 157 two-stage) were randomized. Groups were similar with respect to demographics and host classification. After excluding patients who died or were lost to follow-up, 258 of the 323 patients had 2-year follow-up (135 one-stage and 123 two-stage). The rate of patient loss to follow-up was similar between the treatment groups. RESULTS: Sixteen patients in the 1-stage group and 9 patients in the 2-stage group died prior to 2-year follow-up. Overall, the 2-year success rate of 1-stage treatment was 97% (131 of 135), while the success of 2-stage treatment was 91% (112 of 123) (p = 0.04). Compared with the 2-stage group, the 1-stage group had 3-times the odds of overall success in a regression analysis (unadjusted odds ratio = 3.22 [95% confidence interval = 1.0 to 10.38]). After adjusting for specific variables (McPherson host grade, resistant organism, and draining sinuses), 1-stage treatment also had 3-times the odds of success. CONCLUSIONS: The results of this prospective randomized trial indicated that 1-stage treatment (97% success) was statistically noninferior to 2-stage treatment (91% success) when treating chronic PJI following primary total hip or knee arthroplasty, provided the protocols described here are explicitly followed. Extrapolation to other patient cohorts and clinical situations should be avoided. LEVEL OF EVIDENCE: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
引用
- Fehring TK, Otero JE, Fehring KA, et al. One-Stage Versus Two-Stage Exchange Arthroplasty for Periprosthetic Joint Infection: A Prospective Randomized Trial. J Bone Joint Surg Am. 2026. PMID: 41921050. doi:10.2106/JBJS.25.00713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。